Draft:Vishal Chakravarty

Early career

Prior to founding NovaPharm Healthcare, Chakravarty worked at Swiggy, the Indian food delivery platform, during its hypergrowth period between April 2019 and May 2020, when the company was processing approximately 1.4 million orders per day across more than 325 cities in India and had achieved a valuation of $3.6 billion.^[4]

Following his departure from Swiggy, Chakravarty transitioned into the United Kingdom pharmaceutical sector, undertaking self-directed study of MHRA regulatory frameworks, GDP compliance standards, the Falsified Medicines Directive (FMD), and parallel import licensing procedures before founding his first pharmaceutical company.^[5]

NovaPharm Healthcare Ltd

Chakravarty founded NovaPharm Healthcare Ltd in the United Kingdom as a specialist pharmaceutical distribution and parallel import licensing company. The company is registered under [[Companies House]] number 16716501, with its registered office at Flat 72 Archer Court, 21 High Street, Feltham, England, TW13 4AG.^[1] The company's registered Standard Industrial Classification (SIC) codes are 21100 (Manufacture of basic pharmaceutical products) and 46460 (Wholesale of pharmaceutical goods).^[1]

NovaPharm Healthcare operates under MHRA regulatory oversight and focuses on four core service areas: parallel import product licensing (PLPI), EU-GMP supplier qualification, NHS market access, and post-Brexit pharmaceutical distribution strategy.^[3][6]

The company operates a three-pillar sourcing strategy combining direct GMP partnerships with verified manufacturers in India and the EU, MHRA-approved PLPI licensing for EU-authorised medicines supplied to the UK market, and a verified European wholesaler network spanning Germany, Poland, Romania, and the Netherlands.^[3][7]

NovaPharm Healthcare serves NHS Trusts and hospitals, independent pharmacies, and licensed wholesalers, offering enterprise procurement partnerships for acute and specialist hospital organisations seeking predictable supply and regulatory transparency, with typical cost optimisation estimates ranging from approximately 8 to 25 percent depending on product mix and volumes.^[3]

The company maintains GxP-compliant pharmacovigilance systems with MHRA Yellow Card integration, real-time batch tracking, and temperature-validated cold-chain logistics infrastructure.^[3][8]

Novapharm Innovation Technology

Chakravarty is also the founder of Novapharm Innovation Technology, a pharmaceutical services firm providing regulatory submissions, research and development within GMP frameworks, patent strategy and intellectual property rights management, and end-to-end pharmaceutical project lifecycle management.^[2]

The firm operates across three major regulatory environments: Health Canada and the United States FDA in North America, including NDS, ANDS, and IND/NDA pathways; the MHRA in the United Kingdom, including parallel import licensing and marketing authorisation applications; and the European Medicines Agency (EMA) in the European Union, including centralised and decentralised regulatory procedures, hybrid applications, and mutual recognition procedures.^[2][9]

Parallel import licensing

Chakravarty has developed specialist expertise in MHRA parallel import product licensing (PLPI), the regulatory pathway through which pharmaceutical products authorised in one country are imported and resold in another — in the UK's case, medicines approved in EEA member states imported and relicensed for supply to the UK market.^[10]

In his published analysis, Chakravarty notes that the total European market for parallel imported pharmaceuticals is valued at €5.5 billion, with the UK parallel import market representing approximately £750 million annually and accounting for approximately 9% of medicines dispensed in UK pharmacies.^[10][11]

Post-Brexit regulatory navigation

Following the United Kingdom's withdrawal from the European Union, Chakravarty has focused on the regulatory divergence between the MHRA and the EMA. He has written on the implications of the Windsor Framework, implemented on 1 January 2025, under which the MHRA now licenses all medicines across the entire United Kingdom including Northern Ireland, and Parallel Distribution Notices (PDNs) previously valid under EU law are no longer valid in Northern Ireland.^[12][10]

NHS market access and NICE HTA

Chakravarty has published analysis of the NICE Health Technology Assessment (HTA) process and its strategic implications for pharmaceutical companies seeking NHS formulary access, covering appraisal types, submission evidence requirements, value-based pricing strategy, and Commercial Medicines Unit negotiations.^[13]

Yakuji Nippo

Chakravarty is a contributing author to Yakuji Nippo (薬事日報), Japan's foremost pharmaceutical industry daily newspaper, founded in 1945 and published by Yakuji Nippo Co. Ltd. in Tokyo, Japan. The publication is read by pharmaceutical companies, regulators, and healthcare professionals across Japan and the Asia-Pacific region.^[14] He has published four articles available in English and Japanese:

1. "UK Pharmaceutical Market Access Post-Brexit" (2024)^[12]
2. "MHRA PLPI Licensing: A Practical Guide for International Pharmaceutical Companies" (2024)^[6]
3. "Parallel Import Strategy in UK and EU Markets" (2024)^[11]
4. "NICE HTA: A Strategic Framework for NHS Market Entry" (2025)^[13]

Essays

Chakravarty publishes long-form essays on pharmaceutical strategy, regulated industry entrepreneurship, and career strategy on his personal website.^[15] Published essays include:

• "How to Win When the Odds Are Against You" (January 2026) — an analysis of structural

disadvantage in business and the strategic use of asymmetry and disciplined capital allocation.^[16]

• "Regulated Industries: Building Where Others Won't" (January 2026) — an analysis of why

regulated industries create sustainable competitive moats and why most founders avoid them.^[5]

• "What Parallel Import Actually Means" (January 2026) — a practitioner's breakdown of

pharmaceutical parallel import, covering the €5.5 billion European market, MHRA PLPI mechanics, and post-Brexit changes.^[10]

• "Why I Left Swiggy" (January 2026) — an account of his departure from the Indian food

delivery sector and the strategic rationale for entering UK pharmaceutical distribution.^[4]